[go: up one dir, main page]

ES2173883T3 - Utilizacion de derivados de piperacina-acetamida contra los daños de reperfusion. - Google Patents

Utilizacion de derivados de piperacina-acetamida contra los daños de reperfusion.

Info

Publication number
ES2173883T3
ES2173883T3 ES93201656T ES93201656T ES2173883T3 ES 2173883 T3 ES2173883 T3 ES 2173883T3 ES 93201656 T ES93201656 T ES 93201656T ES 93201656 T ES93201656 T ES 93201656T ES 2173883 T3 ES2173883 T3 ES 2173883T3
Authority
ES
Spain
Prior art keywords
piperacine
acetamide derivatives
derivatives against
compound
against reperfusion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93201656T
Other languages
English (en)
Inventor
Belle Herman Van
Laerhoven Willy Johannes C Van
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Application granted granted Critical
Publication of ES2173883T3 publication Critical patent/ES2173883T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A61K38/166—Streptokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Protection Of Pipes Against Damage, Friction, And Corrosion (AREA)
  • Dicing (AREA)
  • Golf Clubs (AREA)
  • Professional, Industrial, Or Sporting Protective Garments (AREA)
  • Suspension Of Electric Lines Or Cables (AREA)
  • Branch Pipes, Bends, And The Like (AREA)
  • Paper (AREA)
  • External Artificial Organs (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Production Of Liquid Hydrocarbon Mixture For Refining Petroleum (AREA)

Abstract

EL COMPUESTO (/)-(-)-2-(AMINOCARBONIL)-N-(4-AMINO-2,6-DICLOROFENIL)-4-[5,5-BIS(4FLUOFENIL)PENTIL]-1-PIPERAZINACETAMIDA, LAS SALES DE ADICION ACIDAS FARMACEUTICAMENTE ACEPTABLES DEL MISMO O HIDRATOS DEL MISMO; UN PROCESO PARA LA PREPARACION DE DICHO COMPUESTO Y COMPOSICIONES FARMACEUTICAS QUE CONTIENEN DICHO COMPUESTO COMO INGREDIENTE ACTIVO.
ES93201656T 1989-11-22 1990-11-19 Utilizacion de derivados de piperacina-acetamida contra los daños de reperfusion. Expired - Lifetime ES2173883T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44014289A 1989-11-22 1989-11-22
SG118494A SG118494G (en) 1989-11-22 1994-08-20 Method of preventing or limiting reperfusion damage

Publications (1)

Publication Number Publication Date
ES2173883T3 true ES2173883T3 (es) 2002-11-01

Family

ID=26664237

Family Applications (2)

Application Number Title Priority Date Filing Date
ES93201656T Expired - Lifetime ES2173883T3 (es) 1989-11-22 1990-11-19 Utilizacion de derivados de piperacina-acetamida contra los daños de reperfusion.
ES90917677T Expired - Lifetime ES2053208T3 (es) 1989-11-22 1990-11-19 Metodo para prevenir o limitar el daño por reperfusion.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES90917677T Expired - Lifetime ES2053208T3 (es) 1989-11-22 1990-11-19 Metodo para prevenir o limitar el daño por reperfusion.

Country Status (22)

Country Link
EP (2) EP0455789B1 (es)
JP (1) JP2574585B2 (es)
KR (1) KR0165686B1 (es)
AT (2) ATE213943T1 (es)
AU (1) AU632888B2 (es)
CA (1) CA2044143C (es)
CY (1) CY1869A (es)
DE (2) DE69033926T2 (es)
DK (2) DK0455789T3 (es)
ES (2) ES2173883T3 (es)
FI (1) FI109694B (es)
HK (1) HK115095A (es)
HU (1) HU215847B (es)
IE (1) IE65121B1 (es)
IL (1) IL96390A (es)
NO (2) NO304519B1 (es)
NZ (1) NZ236168A (es)
PT (2) PT95959B (es)
RU (1) RU2093156C1 (es)
SG (1) SG118494G (es)
WO (1) WO1991007967A2 (es)
ZA (1) ZA909345B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9202266D0 (sv) * 1992-07-31 1992-07-31 Kabi Pharmacia Ab Novel piperazine carboxamides
SE9504661D0 (sv) 1995-12-22 1995-12-22 Astra Pharma Inc New compounds
RU2216549C2 (ru) * 1997-11-07 2003-11-20 Дайити Фармасьютикал Ко., Лтд. Пиперазин-циклодекстриновый комплекс и лекарственное средство, содержащее указанный комплекс
US6683100B2 (en) 1999-01-19 2004-01-27 Novartis Ag Organic compounds
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
SE9904674D0 (sv) 1999-12-20 1999-12-20 Astra Pharma Inc Novel compounds
SE9904673D0 (sv) 1999-12-20 1999-12-20 Astra Pharma Inc Novel compounds
SE0001209D0 (sv) 2000-04-04 2000-04-04 Astrazeneca Canada Inc Novel compounds
US6573264B1 (en) * 2000-10-23 2003-06-03 Cv Therapeutics, Inc. Heteroaryl alkyl piperazine derivatives
PT1395567E (pt) 2001-05-18 2009-03-26 Astrazeneca Ab Derivados de 4(fenil-piperazinil-metil)benzamida e sua utilização para o tratamento da ansiedade da dor ou de distúrbios gastrointestinais
SE0203300D0 (sv) 2002-11-07 2002-11-07 Astrazeneca Ab Novel Compounds
SE0203302D0 (sv) 2002-11-07 2002-11-07 Astrazeneca Ab Novel Compounds
SE0203303D0 (sv) 2002-11-07 2002-11-07 Astrazeneca Ab Novel Compounds
US20090018351A1 (en) * 2003-11-12 2009-01-15 Dr. Reddy's Laboratories, Inc. Preparation of escitalopram
DK1781631T3 (da) 2004-08-02 2012-05-14 Astrazeneca Ab Diarylmethylpiperazinderivater, præparater dermed og anvendelser deraf
FR2946340B1 (fr) 2009-06-05 2011-06-24 Galderma Res & Dev Nouveaux n-phenyl acetamie, inhibiteurs de l'enzyme soat-1, compositions pharmaceutiques et cosmetiques les contenant.
KR101900124B1 (ko) 2014-06-25 2018-09-18 전남대학교산학협력단 전복 박리용 조성물
KR101644299B1 (ko) 2014-07-22 2016-08-02 주식회사 엔바이로젠 오미자 및 삼채 추출물을 유효성분으로 포함하는 전복 박리용 조성물

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4766125A (en) * 1981-06-23 1988-08-23 Janssen Pharmaceutica N.V. N-aryl-piperazinealkanamides useful for protecting hearts from myocardial injury caused by ischaemia, anoxia or hypoxia
NZ223847A (en) * 1987-04-01 1989-12-21 Janssen Pharmaceutica Nv Substituted piperazine derivatives and pharmaceutical compositions

Also Published As

Publication number Publication date
HU9102436D0 (en) 1991-12-30
FI109694B (fi) 2002-09-30
JP2574585B2 (ja) 1997-01-22
IE904209A1 (en) 1991-05-22
NO912511L (no) 1991-08-26
DK0577171T3 (da) 2002-06-03
CA2044143C (en) 2002-11-19
HUT58709A (en) 1992-03-30
ES2053208T3 (es) 1994-07-16
FI913433A0 (fi) 1991-07-16
IL96390A (en) 1995-06-29
SG118494G (en) 1994-11-25
NO912511D0 (no) 1991-06-26
EP0455789A1 (en) 1991-11-13
DE69033926D1 (de) 2002-04-11
DE69033926T2 (de) 2002-10-24
NO311701B1 (no) 2002-01-14
NO304519B1 (no) 1999-01-04
EP0577171A2 (en) 1994-01-05
DE69007471T2 (de) 1994-06-23
DE69007471D1 (de) 1994-04-21
IL96390A0 (en) 1991-08-16
PT95959B (pt) 1998-08-31
AU632888B2 (en) 1993-01-14
AU6876391A (en) 1991-06-26
PT102145B (pt) 2002-06-28
WO1991007967A2 (en) 1991-06-13
KR920700644A (ko) 1992-08-10
ZA909345B (en) 1992-08-26
PT102145A (pt) 1999-10-29
NO982078D0 (no) 1998-05-07
CY1869A (en) 1996-04-05
KR0165686B1 (ko) 1999-01-15
ATE102831T1 (de) 1994-04-15
EP0577171A3 (en) 1994-06-29
EP0455789B1 (en) 1994-03-16
PT95959A (pt) 1991-09-13
DK0455789T3 (da) 1994-04-05
HK115095A (en) 1995-07-21
NZ236168A (en) 1993-05-26
WO1991007967A3 (en) 1991-07-11
ATE213943T1 (de) 2002-03-15
HU215847B (hu) 1999-04-28
NO982078L (no) 1991-08-26
CA2044143A1 (en) 1991-05-23
EP0577171B1 (en) 2002-03-06
RU2093156C1 (ru) 1997-10-20
IE65121B1 (en) 1995-10-04

Similar Documents

Publication Publication Date Title
ES2173883T3 (es) Utilizacion de derivados de piperacina-acetamida contra los daños de reperfusion.
PT750618E (pt) Derivados de oxazolidinona e composicoes farmaceuticas que os contem
PT97689A (pt) Processo para a preparacao de composicoes farmaceuticas incorporando como ingrediente activo isoxazol-4-carboxilamida e hidroxialquilideno-cianoacetamida
ECSP941104A (es) Derivados de 2,6 diaminopurina, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
ES2055860T3 (es) Derivados 2-aminopirimidinona.
ES2145774T3 (es) Derivados de adenosina que tienen actividad agonista en a2.
ES2040234T3 (es) Derivados del tetrahidronaftaleno y medicamentos que los contienen.
AR020001A1 (es) COMPUESTOS ACTIVADORES DE hPPARGAMMA Y hPPARALFA, COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN, METODO PARA EL TRATAMIENTO Y/O PREVENCION DE UNAENFERMEDAD MEDIADA POR LOS MISMOS, Y SU USO PARA LA ELABORACION DE UN MEDICAMENTO
ES2083668T3 (es) Combinaciones antiviricas que contienen analogos de nucleosidos.
MX9206305A (es) Bifenilpiridonas substitutas, procedimiento para su obtencion y medicamento que los contiene.
ES2180592T3 (es) Formulaciones en aerosol libres de clorofluorocarbonos.
ES2061848T3 (es) Compuestos triciclos, procedimientos para su preparacion y composiciones farmaceuticas que los comprenden.
NO883229D0 (no) Nye benzimidazolderivater, fremgangsmaate for deres fremstilling og farmasoeytisk preparat inneholdende slike derivater.
AR019496A1 (es) Azalidas de 13 miembros, composiciones farmaceuticas, uso en la preparacion de medicamentos y preparacion de los mismos
MX24839A (es) 3-arilcarbonil-1-aminoalquilo-1h-indoles, proceso para su preparacion y composicion farmaceutica quelos contiene.
PT101725A (pt) Processo para a preparacao de um composto de diarilo anti-aterosclerotico e de composicoes farmaceuticas que o contem
AR032138A1 (es) Derivados de 6-hidroxi-indazol, una composicion oftalmica, y el uso de dichos derivados para la manufactura de un medicamento para el tratamiento de glaucoma
ECSP930933A (es) Composicion farmaceutica y procedimiento para prepararla
ES2109993T3 (es) Derivados de 4-desoxi-4-epipodofilotoxina o sus sales farmaceuticamente aceptables.
MX9400801A (es) Agentes colinergicos de oxima de tetrahidropiridinna o-substituidos estabilizados con almidon.
MX9301157A (es) Derivados de bencimidazolona, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
ES2091183T3 (es) Metodo para mejorar el sueño.
AR002027A1 (es) Formulaciones transdermicas y proceso para prepararlas.
BR9611276A (pt) Composto formulação farmacêutica processo para tratamento ou profilaxia de doenças ou condições de seres humanos e uso de um composto
AR006345A1 (es) Una composicion farmaceutica para administracion oral que comprende un inhibidor de proteasa del vih y un derivado de tocoferol soluble en agua, y un metodo para preparar dicha composicion.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 577171

Country of ref document: ES